VK2735_Dosage, benefits & legal status
An experimental weight-loss compound in the tirzepatide family, as a shot or pill.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is VK2735?
Plain language first. The technical label stays, but it never stands alone.Overview
What it's used for
An experimental weekly (and oral) weight-loss compound in the same family as tirzepatide, with promising early results.
How does VK2735 work?
What it does in the body, and where.VK2735 targets the same two receptors as tirzepatide, GLP-1 and GIP. It is being developed as both an injection and a pill.
- 01GLP-1 and GIP togetherThe receptor pair that produced the largest approved weight-loss results so far.
- 02An oral version is in trials tooMost peptides cannot survive digestion. If the tablet works, it removes the injection barrier that keeps many people away from this class.
- 03Still investigationalPhase 2 results are promising and phase 3 is running. Nothing here is approved.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Weight loss, as either a pill or an injectionInvestigational
The published record
Papers and trials about VK2735
Searched: VK2735, VK-2735.
9 papers tagged human · 1 not reviews or lab · 1 clinical trial publications
8 registered trials · none with posted results
Furthest stage reached: Phase 3, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about VK2735
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
10 mg
Half-life
170 to 250 hours
How much, and do you cycle it?
The range, and whether you take breaks.2.5 up to 15 mg per week (start low, increase slowly), weekly. Not cycled in the trials Trial dose
Given continuously for the whole study period: VANQUISH-1, 78 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break.
170 to 250 hoursTrial protocol
From a company disclosure rather than a full pharmacokinetic paper. The oral formulation is a separate product with its own profile.
Source: Viking Therapeutics phase 1 disclosure, 28 March 2023. Phase 2 VENTURE, Obesity 2026, DOI 10.1002/oby.70106
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized VK2735 keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- No formal contraindications established
- Pregnancy
Stop and get help
- Vomiting badly enough that you cannot keep fluids down
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Common effects
- Nausea in roughly 43 to 58% depending on the form
- Vomiting in roughly 18 to 26%
- At the highest oral dose, 38% stopped because of stomach effects
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is VK2735 approved?
And where the numbers on this page come from.No. VK2735 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin, or by mouth
- Checked22 July 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesNone traced yet.
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
What else is like VK2735?
Others in GLP-1 agonists, side by side.If you're weighing VK2735, it's worth reading Zabopegdutide (DD01), Zovaglutide (ZT-002), and Retatrutide in the same class.
An experimental weight-loss compound in the tirzepatide family, as a shot or pill.
- Dose
- 2.5 up to 15 mg per week (start low, increase slowly)
- How often
- Weekly
Nearly the same peptide as efinopegdutide, carried on a large PEG instead of an antibody fragment. In a 67-person phase 2, 76% on the drug cut liver fat by at least 30% in 12 weeks, against 12% on placebo.
- Dose
- 20 mg weekly for 2 weeks, then 40 mg weekly (phase 2 trial)
- How often
- Weekly
An experimental once-a-month weight-loss shot.
- Dose
- 80 up to 160 mg per month (trial doses)
- How often
- Monthly
An experimental weekly shot with some of the biggest weight-loss numbers yet in trials.
- Dose
- 1 up to 12 mg per dose (start low, increase slowly)
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
No primary source has been traced for this compound yet. Treat everything on this page as unverified until one is. How we grade evidence
Beyond these, 9 records are indexed. Browse the records
Read what the maintenance study tested, and what it did not; reduced-frequency dosing followed a weekly run-in.